BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136]
URL: https://www.wjgnet.com/1007-9327/full/v25/i25/3136.htm
Number Citing Articles
1
Matthias Ocker, Daniel Neureiter. Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systemsExpert Review of Gastroenterology & Hepatology 2021; 15(2): 111 doi: 10.1080/17474124.2021.1829472
2
Xin Qing, Wenjing Xu, Jingjing Zong, Xuanlong Du, Hao Peng, Yewei Zhang. Emerging treatment modalities for systemic therapy in hepatocellular carcinomaBiomarker Research 2021; 9(1) doi: 10.1186/s40364-021-00319-3
3
Malwina Sosnowska, Marta Kutwin, Barbara Strojny, Mateusz Wierzbicki, Dominik Cysewski, Jarosław Szczepaniak, Mateusz Ficek, Piotr Koczoń, Sławomir Jaworski, André Chwalibog, Ewa Sawosz. Diamond Nanofilm Normalizes Proliferation and Metabolism in Liver Cancer CellsNanotechnology, Science and Applications 2021; : 115 doi: 10.2147/NSA.S322766
4
Aiqing Ma, Rui Zhang. <p>Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer</p>Cancer Management and Research 2020; : 3537 doi: 10.2147/CMAR.S240064
5
Hong Zhao, Yujie Wang, Yufeng Liu, Xiaohua Hao, Hongshan Wei, Wen Xie. The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular MechanismAnalytical Cellular Pathology 2019; 2019: 1 doi: 10.1155/2019/5901083
6
Yinjiang Zhang, Hongyun Wei, Lu Fan, Mingyan Fang, Xu He, Binan Lu, Zongran Pang. CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma MicroenvironmentFrontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.681372
7
Chengpeng Yu, Dean Rao, He Zhu, Qiumeng Liu, Wenjie Huang, Long Zhang, Huifang Liang, Jia Song, Zeyang Ding, Gitana Maria Aceto. TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/4708439
8
SunilGowda Sunnaghatta Nagaraja, Umadevi Subramanian, Devipriya Nagarajan. Radiation-induced H3K9 methylation on E-cadherin promoter mediated by ROS/Snail axis : Role of G9a signaling during lung epithelial-mesenchymal transitionToxicology in Vitro 2021; 70: 105037 doi: 10.1016/j.tiv.2020.105037
9
Bart Vanderborght, Kevin De Muynck, Sander Lefere, Anja Geerts, Helena Degroote, Xavier Verhelst, Hans Van Vlierberghe, Lindsey Devisscher. Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse modelOncotarget 2020; 11(48): 4504 doi: 10.18632/oncotarget.27830
10
Hara Afaloniati, Katerina Angelopoulou, Alexander Giakoustidis, Alexandros Hardas, Athanasios Pseftogas, Kali Makedou, Athanasios Gargavanis, Thomas Goulopoulos, Stavros Iliadis, Vasileios Papadopoulos, Apostolos Papalois, George Mosialos, Theofilos Poutahidis, Dimitrios Giakoustidis. <p>HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice</p>OncoTargets and Therapy 2020; : 5575 doi: 10.2147/OTT.S250233
11
Matthias Ocker, Christian Mayr, Tobias Kiesslich, Sebastian Stintzing, Daniel Neureiter. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the FutureCancers 2021; 13(7): 1558 doi: 10.3390/cancers13071558
12
Leandro Ryuchi Iuamoto, Alberto Meyer. Commentary on "The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection"International Journal of Surgery 2019; 72: 144 doi: 10.1016/j.ijsu.2019.10.045
13
Abdullah Al Mamun, Yanqing Wu, Chang Jia, Fahad Munir, Kasfia Jahan Sathy, Tamanna Sarker, Ilma Monalisa, Kailiang Zhou, Jian Xiao. Role of pyroptosis in liver diseasesInternational Immunopharmacology 2020; 84: 106489 doi: 10.1016/j.intimp.2020.106489
14
Baozhu Zhang, Qing Zhou, Qiankun Xie, Xiaohui Lin, Wenqiang Miao, Zhaoguang Wei, Tingting Zheng, Zuoliang Pang, Haosheng Liu, Xi Chen. SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinomaAging 2021; 13(2): 2803 doi: 10.18632/aging.202329
15
Christoph Roderburg, Alexander Wree, Münevver Demir, Moritz Schmelzle, Frank Tacke. The role of the innate immune system in the development and treatment of hepatocellular carcinomaHepatic Oncology 2020; 7(1): HEP17 doi: 10.2217/hep-2019-0007
16
Xiaoming Dai, Ruixue Huang, Sai Hu, Yao Zhou, Xiaoya Sun, Pucheng Gui, Zijian Yu, Pingkun Zhou. A novel miR-0308-3p revealed by miRNA-seq of HBV-positive hepatocellular carcinoma suppresses cell proliferation and promotes G1/S arrest by targeting double CDK6/Cyclin D1 genesCell & Bioscience 2020; 10(1) doi: 10.1186/s13578-020-00382-7
17
Bart Vanderborght, Sander Lefere, Hans Van Vlierberghe, Lindsey Devisscher. The Angiopoietin/Tie2 Pathway in Hepatocellular CarcinomaCells 2020; 9(11): 2382 doi: 10.3390/cells9112382
18
Alexandru Blidisel, Iasmina Marcovici, Dorina Coricovac, Florin Hut, Cristina Adriana Dehelean, Octavian Marius Cretu. Experimental Models of Hepatocellular Carcinoma—A Preclinical PerspectiveCancers 2021; 13(15): 3651 doi: 10.3390/cancers13153651
19
Hara Afaloniati, Theofilos Poutahidis, Alexander Giakoustidis, Athanasios Gargavanis, Dimitrios Giakoustidis, Katerina Angelopoulou. Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway componentsMolecular Biology Reports 2021; 48(1): 551 doi: 10.1007/s11033-020-06089-9
20
Kurt Sartorius, Ping An, Cheryl Winkler, Anil Chuturgoon, Xiaodong Li, Julia Makarova, Anna Kramvis. The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA DysregulationFrontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.661204
21
Matthew R. Woeste, Anne E. Geller, Robert C. G. Martin, Hiram C. Polk. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular CancerAnnals of Surgical Oncology 2021; 28(3): 1499 doi: 10.1245/s10434-020-09414-5
22
AM Kabel, HH Arab, MA Abd Elmaaboud. Attenuation of diethyl nitrosamine-induced hepatocellular carcinoma by taxifolin and/or alogliptin: The interplay between toll-like receptor 4, transforming growth factor beta-1, and apoptosisHuman & Experimental Toxicology 2021; : 096032712110084 doi: 10.1177/09603271211008496
23
Payal Deepak, Rajinikanth Siddalingam, Praveen Kumar, Sneha Anand, Sunita Thakur, Balasubramaniam Jagdish, Shweta Jaiswal. Gene based nanocarrier delivery for the treatment of hepatocellular carcinomaJournal of Drug Delivery Science and Technology 2020; 59: 101837 doi: 10.1016/j.jddst.2020.101837
24
C. Lv, X. J. Li, L. X. Hao, S. Zhang, Z. Song, X. D. Ji, B. Gong. Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinomaClinical and Translational Oncology 2021;  doi: 10.1007/s12094-021-02673-y
25
Prashika Singh, Dylan Kairuz, Patrick Arbuthnot, Kristie Bloom. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approachWorld Journal of Gastroenterology 2021; 27(23): 3182-3207 doi: 10.3748/wjg.v27.i23.3182
26
The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical ImplicationsInternational Journal of Molecular Sciences 2019; 20(21): 5266 doi: 10.3390/ijms20215266